RFK Jr. and FDA's Makary Overstated Hormone Therapy's Disease-Prevention Benefits

At the announcement, HHS Secretary Robert F. Kennedy Jr. said hormone therapy reduces "Alzheimer's disease by 35%" and cognitive decline by 64%, while FDA Commissioner Marty Makary said it cuts cardiovascular disease risk "by as much as 50%" and called it "life-saving" ^[1].

These specific percentages — not the warning-label change itself — are what independent researchers and fact-checkers dispute.

Dr. Pauline Maki told FactCheck.org the 35% figure traces to a single 1996 observational study of a California retirement community and called it "misleading and inaccurate"; more recent studies with over 60,000 participants combined found "zero evidence for a reduction" in dementia risk, with some finding elevated risk ^[1].

The Menopause Society has concluded hormone therapy "is not recommended at any age to prevent or treat a decline in cognitive function or dementia," citing what it describes as consistent scientific evidence ^[1].

Multiple larger, more recent studies contradict the single small study behind the 35% dementia claim.

WHI investigator Dr. Marcia Stefanick told FactCheck.org that observational studies showing a cardiovascular benefit were confounded because hormone-therapy users tended to be "less obese, less likely to smoke, more physically active," and that the randomized WHI trials themselves "did not identify cardioprotective effects" ^[1].

Dr. Chrisandra Shufelt said researchers "can't make these very large sweeping claims" about heart protection "until we have that next trial" ^[1].

The randomized WHI trials — the strongest evidence available — found no heart-protective effect, unlike the observational data officials cited.

Former WHI project officer Jacques Rossouw called officials' characterization of the breast-cancer findings "dead wrong"; the original 2003 WHI analysis found a statistically significant 24% increase in breast cancer cases among users of combined hormone therapy ^[1].

Separately, the North American Menopause Society's 2022 position statement states breast cancer risk "does not increase appreciably with short-term use of estrogen-progestogen therapy and may be decreased with estrogen alone" — a more measured framing than either "safe" or "dangerous" ^[5].

Breast-cancer risk depends heavily on formulation and duration of use, nuance that is lost in blanket claims on either side.

Cedars-Sinai's Dr. Sharon Winer noted after the FDA's change that "there's a lot we still don't know" and that hormone therapy "won't solve every age-related health concern," adding that women with a personal history of hormone-driven cancers should still avoid systemic therapy ^[4].

Clinical guidance continues to flag a personal or family history of blood clots, breast/uterine/ovarian cancer, and heart, liver, or gallbladder disease as reasons a patient and doctor may need to avoid or adjust hormone therapy, and formulation matters too — combination therapy adds progesterone specifically to lower the endometrial-cancer risk that comes with estrogen alone ^[6].

Medical groups' separate timing guidance — that benefits most clearly outweigh risks for women under 60 or within 10 years of menopause onset — predates and is distinct from the disputed disease-prevention percentages ^[3][5].

A warning-label change doesn't erase the need for an individualized conversation about personal and family health history.

Claims about hormone therapy following the FDA's November 2025 warning change fall into two separate buckets: the label change itself is grounded in a legitimate re-reading of WHI data for younger, recently menopausal women ^[2][3], but the specific disease-prevention percentages cited by RFK Jr. and Makary — up to 50% less heart disease, 35% less Alzheimer's risk — are contradicted by the same randomized-trial data and by independent researchers ^[1]. Neither "hormone therapy is dangerous" nor "hormone therapy prevents heart disease and dementia" holds up; risks and benefits still depend on a patient's age, time since menopause, formulation, and personal and family health history, decided together with a healthcare provider ^[1][5][6].